TERT (telomerase and reverse transcriptase) promoter mutations, H3F3A (replication-independent histone 3.3 linked to high-grade gliomas) alterations, and methylation of MGMT (O6-methylguanine-DNA methyltransferase) promoters were proposed as potential markers of GBM (Śledzińska et al., 2021). This evidence concerns the gene MGMT and central nervous system cancer.